2016年6月24-25日,临床肿瘤学新进展学术研讨会——Best of ASCO Event in China 2016在杭州召开。25日下午的泌尿系统肿瘤专场上,来自中山大学肿瘤防治中心,中国抗癌协会泌尿生殖系肿瘤专业委员会副主任委员周芳坚对三项泌尿系统肿瘤的重要研究进行评述。
三项研究摘要编号和题目:
Abstract 5001
A randomized phase III trial between adjuvant docetaxel and surveillance after radical prostatectomy for high risk prostate cancer: Results of SPCG12
Abstract 4506
Overall survival (OS) in METEOR, a randomized phase 3 trial of cabozantinib (Cabo) versus everolimus (Eve) in patients (pts) with advanced renal cell carcinoma (RCC).
Abstract LBA4500
Atezolizumab (atezo) as first-line (1L) therapy in cisplatinineligible locally advanced/metastatic urothelial carcinoma (mUC):Primary analysis of IMvigor210 cohort 1.
会议专题》》》2016临床肿瘤学新进展学术研讨会(BOA)